Fexitas Special Precautions

Encephalopathy: Beta-lactams, including Cefixime (Fexitas), predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment.
Severe cutaneous adverse reactions: Severe cutaneous adverse reactions (SCARS) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS) drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in association with cefixime (Fexitas). Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. Treatment should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of skin hypersensitivity.
Cefixime (Fexitas) should be given with caution to patients who have shown hypersensitivity to other drugs.
Hypersensitivity to penicillins: As with other cephalosporins, cefixime (Fexitas) should be given with caution to patients with a history of hypersensitivity to penicillin, as there is some evidence of partial cross-allergenicity between the penicillins and cephalosporins.
Patients have had severe reactions (including anaphylaxis) to both classes of drugs. If an allergic effect occurs with Cefixime (Fexitas), the drug should be discontinued and the patient treated with appropriate agents if necessary.
Hemolytic anemia: Drug-induced hemolytic anemia, including severe cases with a fatal outcome, has been described for cephalosporins (as a class). The recurrence of hemolytic anemia after re-administration of cephalosporins in a patient with a history of cephalosporin (including cefixime)-associated hemolytic anemia has also been reported.
Acute renal failure: As with other cephalosporins, Cefixime (Fexitas) may cause acute renal failure including tubulointerstitial nephritis as an underlying pathological condition. When acute renal failure occurs, Cefixime (Fexitas) should be discontinued and appropriate therapy and/or measures should be taken.
Renal impairment: Cefixime (Fexitas) should be administered with caution in patients with markedly impaired renal function.
Antibiotic-associated colitis: Treatment with broad spectrum antibiotics alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of antibiotic-associated diarrhea. Pseudomembranous colitis is associated with the use of broad-spectrum antibiotics (including macrolides, semi-synthetic penicillins, lincosamides and cephalosporins); it is therefore important to consider its diagnosis in patients who develop diarrhea in association with the use of antibiotics. Symptoms of Pseudomembranous colitis may occur during or after antibiotic treatment.
Management of pseudomembranous colitis should include sigmoidoscopy, appropriate bacteriologic studies, fluids, electrolytes and protein supplementation. If the colitis does not improve after the drug has been discontinued, or if the symptoms are severe, oral vancomycin is the drug of choice for antibiotic-associated pseudomembranous colitis produced by C. difficile. Other causes of colitis should be excluded.
Use in Children: Safety of cefixime (Fexitas) in premature or newborn infant has not been established.